Cancer-Vaccine Report Boosts Dendreon Stock

Dendreon shares rose sharply Tuesday as a scientific article cast a positive light on therapeutic cancer vaccines, a family of newly bioengineered products that includes the company’s flagship prostate-cancer treatment, Provenge.
The Seattle Times